Background: Recent data have shown that cardiotoxicity represents a potentially important side-effect in patients treated with sunitinib. We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent.
introduction
Renal cell carcinoma (RCC) represents the most common kidney cancer [1] . Up to 30% of RCC patients present with metastatic disease [2] and recurrence develops in 40% of those initially treated for a localized tumor [3] .
Until recently, cytokines were widely used as first-line therapy for metastatic disease [4] . Although 5%-10% of patients experience long-term remission with such regimens, most gain limited clinical benefit. Additionally, many patients cannot tolerate treatment-related adverse effects [5] .
The introduction of targeted therapies, such as sunitinib malate, represents a significant shift in the treatment of metastatic RCC. The targeted approach has resulted in improved antitumor efficacy with fewer toxic effects than traditional chemotherapy [6] . Additionally, recent results demonstrated that patients on sunitinib arm also had significantly better quality of life compared with those receiving interferon (IFN)-a [7] . Tyrosine kinase inhibitors, however, also inhibit normal variants of tyrosine kinases in noncancerous cells, which can lead to toxic effects affecting the cardiovascular system [8, 9] . These effects are of special interest in that cardiac reserves may be diminished and because methods to quantify cardiac damage are suboptimal. Additionally, the lack of established criteria makes it problematic to quantify cardiotoxicity. Symptoms of congestive heart failure (CHF) are nonspecific and may be attributed to malignant disease, other treatments or coexisting underlying cardiac disease. Furthermore, tyrosine kinase inhibitor-related cardiac original article *Correspondence to: Dr G. Di Lorenzo, Dipartimento di Endocrinologia e Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy. Tel: +39-081-7463660; Fax: +39-081-8997370; E-mail: giuseppedilorenzoncol@hotmail.com dysfunction may represent only a transient and reversible dysfunction of the myocyte that does not permanently destroy the contractile element. These characteristics make difficult to recognize cardiotoxicity in clinical trials and to appreciate the ultimate clinical importance of this phenomenon [10, 11] . The initial appreciation of cardiotoxicity associated with the use of such agents came from the pivotal phase III trial of the anti-HER-2 mAb trastuzumab in the treatment of metastatic breast cancer [10] . More recently, reports are emerging about the cardiotoxicity of small molecule tyrosine kinase inhibitors including lapatinib [12] .
Most of our knowledge regarding the cardiac effects of sunitinib comes from cancer efficacy trials assessing overall safety and showing different results in terms of cardiotoxicity [6, 13, 14] . Recently, three retrospective analyses have evaluated the cardiotoxicity induced by sunitinib in different cancers suggesting that it might represent an important sunitinib-related adverse event [15] [16] [17] . There were several differences among previous studies such as different types of cancers, different selection criteria, different previous treatments, different follow-ups and different comorbidities. In the first two studies, the majority of patients were enrolled in clinical trials that often do not completely represent the current clinical practice. Thus, the percentage of cardiac sideeffects could be higher. Long-term follow-up was not included in the analysis, so that the impact of the finding of decreased ejection fraction cannot be quantified [15, 16] . Considering the growing use of sunitinib in kidney cancer and other tumor types, it is important that clinicians caring for these patients understand the clinical consequences of sunitinib-related cardiotoxicity in order to prevent and treat it when appropriate.
Our aim was therefore to review cardiac adverse events in patients with metastatic RCC on sunitinib. This analysis represents the largest including only RCC patients and the first considering patients who were all treated off clinical protocol with sunitinib.
materials and methods

study population
From November 2005 to March 2008, 175 patients with metastatic RCC undergoing treatment with sunitinib were identified at eight Italian institutions. Median age was 60 years (range 24-80) and 65.7% were male. The majority (73.1%) received sunitinib as first-line therapy, while 26.9% underwent pretreatment with either IFN or interleukin-2. The median number of sunitinib cycles for patients was 6 (range 1-10).
Seven patients had a prior history of coronary artery disease (4%) and 59 (33.7%) had preexisting hypertension. Thirty patients (17.1% of the study population) were receiving angiotensin-converting enzyme (ACE) inhibitors; 17 (9.7 %) and 12 (6.9 %) received angiotensin receptor blockers (ARBs) and b-blockers, respectively ( Table 1 ). All patients signed an informed consent for their treatment. All the institutional review boards of the participating institutions approved this retrospective study. Patients were included in this analysis if they received all or part of their treatment with sunitinib and underwent a follow-up visit at one of our institutions.
Only patients with adequate medical records, including sufficient data on RCC, as well as cardiac data regarding baseline cardiologic evaluation, treatment and outcome were included in our retrospective analysis. The presence or absence of baseline cardiac risk factors, including hypertension, CHF, coronary artery disease, hyperlipidemia and diabetes, were recorded for all patients. Baseline antihypertensive drugs were also recorded.
cardiovascular assessment
All patients had their blood pressure measured at baseline and weekly at the time of clinic visits. Left ventricular ejection fraction (LVEF) was evaluated with cardiovascular ultrasound at baseline and after each cycle of sunitinib.
In accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE Version 3.0) [18] , hypertension was defined as systolic blood pressure >150 mmHg or as diastolic blood pressure >100 mmHg. Grade 3 hypertension denoted patients who required more than one antihypertensive medication or who needed an increase in the dosage of their antihypertensive medication, prescribed at the discretion of patient's primary physician.
According to CTCAE, four grades of LVEF dysfunction were recorded: grade 1, asymptomatic LVEF <60%-50%; grade 2, asymptomatic LVEF <50%-40%; grade 3, LVEF in the range of 20%-39% or the patient experiences symptomatic CHF responsive to intervention and grade 4, LVEF <20% or refractory CHF. The CHF diagnosis was made according to the Boston criteria [19] .
For patients experiencing symptomatic cardiotoxicity, clinical evaluations and laboratory, radiographic and cardiac tests carried out at the time of diagnosis of cardiotoxicity were reviewed in detail. All cardiologic Table 2 , at pre-sunitinib baseline, 116 patients (66.3%) had normal blood pressure and were not receiving antihypertensive treatment; the remaining 59 (33.7%) had controlled hypertension and were receiving antihypertensive treatment. Sixty-six patients (37.7%) showed grade 1-2 hypertension, while grade 3 hypertension was observed in 17 patients (9.7%). During treatment, grade 3 hypertension was reported after first and second cycles in three patients and in 14 patients after the third sunitinib cycle; seven patients reported grade 3 hypertension after cycle 3, while four and two patients and one patient developed hypertension after cycles 4, 5 and 6, respectively ( Figure 1 ). Among the 17 grade 3 hypertension patients (9.7%), three were normotensive before sunitinib; while 14 were on hypertension treatment (P = 0.03), 13 of these received full dosages of sunitinib while the remaining four received reduced doses (P not significant) ( Figure 2 ). Among those 17 patients, grade 3 LVEF dysfunction and CHF was observed in 12 patients. Those patients required more intensive therapy than before (adding b-blocker, ARB inhibitors and diuretic treatment in seven, three and eight patients, respectively); mean systolic blood pressure and diastolic blood pressure remained above baseline in four patients (23.5%) despite an increase of antihypertensive therapy.
LVEF dysfunction
One hundred and seventy patients (97.1%) had a baseline LVEF ‡50%; the pretreatment mean was 63.5% (SD 66). Only one of our patients had an abnormal baseline LVEF of 48%; this patient with a history of coronary artery disease received a reduced dosage of 37.5 mg/day of sunitinib. Thirty-three patients (18.9%) developed grade 1-3 LVEF dysfunction; we identified 12 patients who developed grade 3 LVEF dysfunction and CHF (6.9%). All grade 3 LVEF dysfunction patients were taken off sunitinib therapy ( Table 2) .
Only two patients reported grade 3 dysfunction before receiving three cycles, while 10 patients showed grade 3 LVEF dysfunction after the third cycle; in fact, five patients, three patients, one patient and one patient reported this toxicity after cycles 3, 4, 5 and 6, respectively ( Figure 3 ). The observed cardiotoxicity occurred 28-180 days after the initiation of sunitinib.
Patients experiencing CHF and grade 3 hypertension are reported in Table 3 : the most common presenting symptoms were fatigue and dyspnea; five patients required hospitalization. Among 12 patients, nine had previous hypertension history and seven patients had a history of previous coronary artery disease. The median number of administered cycles of sunitinib before CHF was 3 (range 3-6). As previously reported, the majority of grade 3 LVEF dysfunction showed concomitant grade 3 hypertension. Five patients (41.7%) had persistent LVEF dysfunction after discontinuation of sunitinib and initiation of standard heart failure therapy while seven (58.3%) had recovery of LVEF value after discontinuation of sunitinib and cardiologic therapy (Figure 4 ).
factors associated with risk of hypertension and cardiotoxicity
Significant univariate associations for predictors of CHF were history of hypertension (P = 0.008), history of coronary heart disease (P = 0.0005) and prior ACE inhibitor treatment (P = 0.04) ( Table 4) . No association was noted with regard to 
discussion
Tyrosine kinase inhibitors also affect pathways in nontumor cells resulting in unexpected toxicity such as cardiotoxicity [8, 9] . The major finding of our retrospective study was that 18.9% of patients developed grade 1-3 LVEF temporally related to the administration, but only 6.9% developed CHF and grade 3 LVEF dysfunction; sunitinib also induced grade 3 hypertension in 9.7% of them.
Multivariate analysis suggested that history of coronary artery disease (OR 18) and hypertension (OR 3) was the only significant independent predictors of CHF.
Most of our knowledge regarding the cardiac effects of sunitinib comes from cancer efficacy trials and two recent retrospective studies in gastrointestinal stromal and kidney cancers [6, [13] [14] [15] . Demetri et al. [13] reported no reduction of mean LVEF in patients with imatinib-resistant gastrointestinal stromal cancer (GIST) who were given the approved sunitinib dose. Motzer et al. in the phase III trial comparing sunitinib versus IFN-a in untreated metastatic RCC reported a 21% decline in LVEF for sunitinib patients versus 12% for those receiving IFN-a [14] . Different study populations and methods of assessment as well as different exposures to the drug might explain these conflicting findings in terms of cardiotoxicity.
Thus, is it possible that longer exposure to sunitinib might cause more important cardiovascular side-effects? A clear dose versus cardiotoxicity relationship, as it is known to exist for anthracyclines, has not been found for sunitinib. This fact, along with the clinical observation that myocardial depression is often transient, suggests that this agent falls within the Ewer Class II group [20] . If we consider that in Motzer study, the percentage of patients experiencing a LVEF dysfunction has increased from 10% in the initial analysis to 21% with longer follow-up [14] , the answer to previous question might be yes. However, the absence of studies designed to assess sunitinibassociated cardiovascular dysfunction leaves many questions unanswered.
Recently, two retrospective analyses have focused on the risk of cardiotoxicity by sunitinib [15, 16] . Chu et al. [15] evaluated the cardiovascular risk associated with sunitinib in patients with metastatic GIST showing that 80% of patients developed New York Heart Association class III-IV heart failure and 47% developed hypertension with grade 3 hypertension occurring in 17% of patients by cycle 3. Telli et al. conducted a retrospective analysis on the cardiotoxicity in patients treated with sunitinib for RCC and GIST. Among 48 treated patients, 15% developed symptomatic grade 3/4 heart failure [16] . Although there were several differences in patient population such as different types of cancer, previous chemotherapeutic regimens, different sunitinib schedules and history of hypertension, our CHF rate (6.9%) is similar to the one (8%) reported by Chu et al. and in both studies, the toxicity appeared after three cycles in the majority of patients. We have found grade 3 hypertension in 9.7% of patients while Chu et al. [15] described grade 3 hypertension in 17% of patients. The higher percentage could be due to a previous treatment with imatinib and anthracycline or a lower use of cardiac medications at baseline in the study of Chu et al. [15] . In the study of Telli et al. [16] , the grade 3-4 heart failure rate was higher (15%) than ours. We can explain differences in those two reports with the different selection of patients: the percentage of those with history of hypertension was higher in the study of Telli et al. (67% versus 31.8% in our report). It should be considered that in the study of Telli et al., there were patients pretreated with other tyrosine kinase inhibitors (sorafenib and imatinib) while in our report there were not.
A prior history of CHF or coronary artery disease conferred increased risk of cardiotoxicity in the study of Telli et al. [16] but there was no correlation with regard to hypertension while in our report also hypertension was strongly associated with CHF. We found that the majority of grade 3 LVEF dysfunction showed concomitant grade 3 hypertension; in fact, 12 patients with grade 3 hypertension reported CHF. The hypertension could contribute to development of LVEF dysfunction as suggested by Chu results [15] .
Recently, Khakoo et al. [17] described six cases (2.7%) of CHF in 224 patients receiving sunitinib for different types of cancer. In this report, symptomatic heart failure occurred soon after initiation of sunitinib with a mean onset of 22 days after initiation and was not completely reversible in most patients. The early appearance of CHF in this study, when compared with our findings, could be due to different population (many patients were pretreated with other tyrosine kinase inhibitors and one patient had also received doxorubicin). Furthermore, although many of the patients treated by Khakoo had RCC, other malignancies were also represented. original article
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The mechanism of CHF associated with sunitinib is unknown. Our findings, in agreement with those by Khakoo, suggest that hypertension may be exerting an important effect and highlight the importance of preclinical studies to determine the mechanism of cardiotoxicity. Grade 3 hypertension and CHF occurred after three cycles after initiation of sunitinib in the majority of our patients and this suggests that the cardiotoxicity is distinct from anthracycline-mediated cardiotoxicity which is dose dependent, often occurring after prolonged exposure [21] . Additionally, it is now known that inflammation, a factor that may be augmented by vascular endothelial cell growth factor (VEGF), plays a role in the development of hypertension; further exploration of this interaction will be required to place VEGF in perspective with regard to patients receiving sunitinib [22] .
Sunitinib-related cardiotoxicity appears to be similar to the one seen in breast cancer with trastuzumab, with no association between dose and duration of drug and subsequent cardiotoxicity [20, 23] .
On the one hand, our report presents some relevant features: it represents the largest retrospective analysis evaluating sunitinib-related cardiovascular toxicity in a single type of tumor (metastatic RCC) and it is the first where all patients are treated off clinical protocol, thus better representing current clinical practice.
Nevertheless, it should be recognized that there are also some drawbacks: being retrospective, our analysis might have underestimated the true incidence of cardiotoxicity due to inherent biases such as different criteria to evaluate preexisting cardiac comorbidity or different methods to evaluate EF dysfunction among the participating institutions. Being a nonrandomized study, for absence of placebo group, it did not estimate the rates of hypertension and CHF in untreated RCC patients.
Besides weekly blood pressure measurement could be not sufficient and many cases remained undiagnosed until causing more significant problems, a daily measurement would be desirable. Thus, our findings need to be corroborated by larger possibly prospective study.
conclusions
Our report highlights the importance of a cardiac monitoring during sunitinib therapy, especially in patients with prior history of hypertension and/or coronary artery disease. We offer some suggestions to be considered with regard to managing patients with risk factors or developing cardiotoxicity. Of course, these suggestions are preliminary and are deemed prudent in view of the present information: for patients with grade 1-2 hypertension, sunitinib can be used, adding antihypertensive drug for patients not receiving it and increasing daily surveillance for blood pressure; for patients developing grade 3 hypertension, it is useful to increase antihypertensive therapy adding a second drug with different mechanism; if grade 3 hypertension disappears (controlled value), the patient might continue with full dose of sunitinib and keep on using antihypertensive drugs, while if the hypertension remains uncontrolled, it is necessary to stop sunitinib for the risk of CHF, prevent or quickly treat CHF and eventually consider a reintroduction of sunitinib at reduced dose. It is important for oncologists to evaluate the risk-benefit ratio for patients with metastatic disease and to consider alternate regimens (immunotherapy, bevacizumab and mammalian target of rapamycin inhibitors) when risks are disproportionate ( Figure 5 ).
The preventive use of antihypertensive drugs, specially ACE inhibitors, in patients receiving chemotherapy could be useful [24] . Considering that the use of sunitinib is rapidly growing, it Annals of Oncology original article will be important for the uro-oncologists to work with cardiologists in managing high-risk patients so as to maximize their survival and to set guidelines for the optimal use of this important new agent.
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